TELIX Pharmaceuticals Ltd (TLX) — Cash Flow Reinvestment Rate
TELIX Pharmaceuticals Ltd (TLX) has a Cash Flow Reinvestment Rate of 0.36x as of June 2025, reinvesting AU$10.13 Million (capex AU$10.13 Million ) from operating cash flow of AU$27.98 Million. Check TLX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
TELIX Pharmaceuticals Ltd Cash Flow Reinvestment Rate (2020–2024)
Historical reinvestment intensity for TELIX Pharmaceuticals Ltd across 3 annual periods. Explore TELIX Pharmaceuticals Ltd (TLX) investment intensity to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for TELIX Pharmaceuticals Ltd (2020–2024)
Year-by-year capital reinvestment analysis for TELIX Pharmaceuticals Ltd. For live market cap and broader valuation context, see TELIX Pharmaceuticals Ltd (TLX) market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (AUD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 3.93x | AU$169.21 Million | AU$43.03 Million | AU$34.03 Million | ▲ +158.9% |
| 2023 | 1.52x | AU$36.28 Million | AU$23.88 Million | AU$10.79 Million | ▲ +110.7% |
| 2020 | 0.72x | AU$1.41 Million | AU$1.96 Million | AU$322.00K | — |